FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy

FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy


Signage is seen outside the U.S. Food and Drug Administration headquarters in White Oak, Maryland, Aug. 29, 2020.

Andrew Kelly | Reuters

The U.S. Food and Drug Administration has warned that some Tydemy birth control pills may not be effective, several days after the manufacturer recalled two batches of the medication that were distributed in the U.S.

The FDA said the pills in question could result in unexpected pregnancy. The agency has not received any reports of adverse events related to Tydemy so far.

related investing news

This little-known pharma stock can rally 50%, Citi says

CNBC Pro

The manufacturer, Lupin Pharmaceuticals, announced a voluntary recall of two batches of Tydemy on July 29. The pills in those batches were distributed in the U.S. between June 3, 2022, and May 31, 2023.

CNBC Health & Science

Read CNBC’s latest health coverage:

Lupin, in a statement last week, said it recalled the batches because pills in one batch tested low for ascorbic acid and “high for a known impurity.” The company said a significant reduction in ascorbic acid could affect the product’s effectiveness.

Lupin said it is notifying wholesalers, distributors, drug chains and supermarkets of the problem and is working to get the affected pills off store shelves. Any store, distributor or wholesaler that has the affected pills in stock should immediately stop distributing them, the company said.

The batches of Tydemy that may not be effective come from lot numbers L200183 and L201560.

Lupin advised patients to continue taking their medication and immediately consult with their doctor about an alternative form of contraception.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More